Breast imaging AI is changing. For years, companies focused on detection accuracy, but now the industry is growing in ways that make a real difference for radiologists and their patients.

Algorithms have reached a point where detection and density solutions from different vendors perform similarly. Companies like ScreenPoint, DeepHealth,, Lunit, Therapixel, Koios, and SeeMode are no longer just competing on cancer detection. Now, they focus on features like using prior exams, classifying breast density, risk scoring, and automating case triage. These tools keep getting better, and the market is starting to notice.

Now, integration is what matters most.

‍

Algorithms Are Settled; The Workflow War Begins

Most radiologists aren’t focused on research papers about algorithms. They care about their workflow. Can they use this tool without adding another system? Will it slow them down? Do they have to enter data in more than one place? Will the results show up when and where they need them?

This is the stage where the market is coming together. Health systems are moving beyond testing several algorithms at once and are now asking tougher questions: Which solutions work well together? Which ones avoid creating extra workflows? Which let me compare results from different vendors without needing a custom data setup?

Fragmentation in breast AI is a real issue, but it’s less about which algorithm is best and more about the challenges of getting them up and running.

‍

The Integration Hurdle: Why Technical Friction Is Slowing Down Life-Saving AI

“Implementing breast AI requires orchestrating DICOM compliance, network bandwidth, specific SOP classes like BTO Slices and Synthetic formats, and ensuring seamless PACS/RIS interoperability,” Josh Dagenhart, our AI Solutions Engineer, explained recently. “Traditionally, this means a complex pre-installation assessment followed by rigorous data stream testing to prevent workflow disruption.”

In simple terms, it’s complicated and slows down adoption.

Radiologists who handle large volumes of breast screenings each day can’t deal with extra complications. If a facility uses DeepHealth or Screenpoint, they shouldn’t have to start a separate project for each vendor. They shouldn’t need special formats or manual fixes.

The consolidation isn’t about removing vendors. It’s about understanding which applications can be stacked to create maximum value on a singular, shared platform.

‍

Removing 'Click Fatigue': How Consolidation Improves the Radiologist's Quality of Life

Ferrum’s approach matches this change. Instead of making radiologists juggle several vendor dashboards and integration points, we serve as a single AI hub. A facility only needs to add one DICOM connection to the mammography machine to access top breast AI solutions. Radiologists see Case Scores, Lesion Scores, and Breast Density results right in their current workstation. There are no special formats, no manual data entry, and no switching between systems.

“By removing technical friction and ‘click fatigue,’ the radiologist isn’t just using AI—they’re seeing a measurable improvement in their daily quality of life,” Josh noted.

That detail matters more than people realize. Radiologist burnout is real. Workflow disruption accelerates it. When adoption tools are frictionless, they actually get used and provide better patient outcomes. When they create friction, they sit idle doing nothing to help patient outcomes.

Clinical results are improving too. Finding breast cancer earlier, especially in younger patients and those with dense breast tissue, is becoming common. Reporting on breast density is becoming standard, not optional. Risk scoring is starting to guide clinical decisions on a larger scale. These advances happen when technology supports radiologists, not when it gets in their way.

‍

A Unified Platform: The Key to Comparing Vendor Performance and Scaling Adoption

There’s another important point that often gets missed. When breast AI vendors work separately, it’s hard to compare their performance fairly. As Josh put it: “Without a unified platform, you’re comparing apples to oranges. One vendor’s Case Score isn’t calibrated the same way as another’s. Radiologists can’t see how algorithms actually perform on the same patient population without custom data work. That opacity is a blocker to scaling what works.”

That’s why this trend toward consolidation is important. When solutions share a single platform with standard outputs, it’s possible to compare them. Validation can be repeated. Health systems can finally answer the key question: which algorithm is really helping my radiologists find more cancers?

Here’s what I’ll be watching in the next year:

• Density classification becomes table stakes. More vendors will incorporate density scoring into core offerings, not as an add-on. Radiologists will expect it as the baseline, not a premium feature.
• Risk scoring hits clinical workflow. We’ll see risk models integrated into reporting templates and connected to follow-up protocols. This drives consistency and better patient management.
• Priors and temporal comparison solidify. The ability to compare current exams with prior studies using AI-guided annotation will shift from a nice-to-have to an essential. This directly impacts detection rates in screening programs.
• Expectations for integration. Health systems will no longer accept isolated vendor solutions. They’ll require systems to work together as a basic need, not just a nice option.

Josh put it plainly: “The facilities winning in breast imaging are the ones automating the entire output pipeline. They’re not manually pulling results from vendor dashboards. They’re ingesting Case Scores, Lesion Scores, and Breast Density classifications directly into the RIS and EHR, then automatically triggering follow-up workflows. The next generation of breast AI adoption won’t be measured by which algorithm you choose. It’ll be measured by how seamlessly it feeds into your clinical operations.”

That’s the shift. Automation replaces manual handoffs. Integration replaces integration as a project.

‍

From Algorithms to Adoption: The Harder Questions Defining the Next Phase of Breast AI

Ferrum’s role in this environment is straightforward: we remove the choice between innovation and integration. Radiologists get access to whatever breast AI solutions are proving themselves in the field, without the deployment headaches that typically come with adoption.

The breast imaging AI market is maturing because the algorithms are good enough to let radiologists and health systems focus on the harder questions. How do I deploy this safely? How do I compare results fairly? How do I know this is actually helping my patients? How do I scale it without breaking my team?

Those are the questions that define the next phase of adoption. And the vendors who answer them clearly will consolidate the market, not through exclusivity, but through trust and simplicity.

Sam Knapp is AI Partnerships Manager at Ferrum Health. Josh Dagenhart is AI Solutions Engineer at Ferrum Health.

‍